Nutritional product marketing firm Usana Health Sciences (USANA) disclosed in a regulatory filing Monday that the Department of Justice and the Securities and Exchange Commission advised the company they’ve closed their respective Foreign Corrupt Practices Act investigations and will not be filing any charges.
In an annual report filed with the SEC in February 2018, USANA disclosed it was conducting a voluntary internal investigation into potential FCPA violations regarding certain conduct and policies at its China subsidiary BabyCare, “including BabyCare’s expense reimbursement policies.” During that time, the company also announced it had voluntarily contacted the SEC and the Justice Department to advise both agencies that an internal investigation was underway.
